<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://physrev.physiology.org">
<title>Physiological Reviews current issue</title>
<link>http://physrev.physiology.org</link>
<description>Physiological Reviews RSS feed -- current issue</description>
<prism:eIssn>1522-1210</prism:eIssn>
<prism:coverDisplayDate>Oct  1 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Physiological Reviews</prism:publicationName>
<prism:issn>0031-9333</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1079?rss=1" />
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1105?rss=1" />
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1153?rss=1" />
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1177?rss=1" />
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1217?rss=1" />
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1269?rss=1" />
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1341?rss=1" />
  <rdf:li rdf:resource="http://physrev.physiology.org/cgi/content/abstract/89/4/1379?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://physrev.physiology.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://physrev.physiology.org/icons/banner/title.gif">
<title>Physiological Reviews</title>
<url>http://physrev.physiology.org/icons/banner/title.gif</url>
<link>http://physrev.physiology.org</link>
</image>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1079?rss=1">
<title><![CDATA[The Function of Activity-Regulated Genes in the Nervous System]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1079?rss=1</link>
<description><![CDATA[ 
<P>The mammalian brain is plastic in the sense that it shows a remarkable capacity for change throughout life. The contribution of neuronal activity to brain plasticity was first recognized in relation to critical periods of development, when manipulating the sensory environment was found to profoundly affect neuronal morphology and receptive field properties. Since then, a growing body of evidence has established that brain plasticity extends beyond development and is an inherent feature of adult brain function, spanning multiple domains, from learning and memory to adaptability of primary sensory maps. Here we discuss evolution of the current view that plasticity of the adult brain derives from dynamic tuning of transcriptional control mechanisms at the neuronal level, in response to external and internal stimuli. We then review the identification of "plasticity genes" regulated by changes in the levels of electrical activity, and how elucidating their cellular functions has revealed the intimate role transcriptional regulation plays in fundamental aspects of synaptic transmission and circuit plasticity that occur in the brain on an every day basis.</P>
]]></description>
<dc:creator><![CDATA[Loebrich, S., Nedivi, E.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00013.2009</dc:identifier>
<dc:title><![CDATA[The Function of Activity-Regulated Genes in the Nervous System]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1103</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1079</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1105?rss=1">
<title><![CDATA[Prions: Protein Aggregation and Infectious Diseases]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1105?rss=1</link>
<description><![CDATA[ 
<P>Transmissible spongiform encephalopathies (TSEs) are inevitably lethal neurodegenerative diseases that affect humans and a large variety of animals. The infectious agent responsible for TSEs is the prion, an abnormally folded and aggregated protein that propagates itself by imposing its conformation onto the cellular prion protein (PrP<SUP>C</SUP>) of the host. PrP<SUP>C</SUP> is necessary for prion replication and for prion-induced neurodegeneration, yet the proximal causes of neuronal injury and death are still poorly understood. Prion toxicity may arise from the interference with the normal function of PrP<SUP>C</SUP>, and therefore, understanding the physiological role of PrP<SUP>C</SUP> may help to clarify the mechanism underlying prion diseases. Here we discuss the evolution of the prion concept and how prion-like mechanisms may apply to other protein aggregation diseases. We describe the clinical and the pathological features of the prion diseases in human and animals, the events occurring during neuroinvasion, and the possible scenarios underlying brain damage. Finally, we discuss potential antiprion therapies and current developments in the realm of prion diagnostics.</P>
]]></description>
<dc:creator><![CDATA[Aguzzi, A., Calella, A. M.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00006.2009</dc:identifier>
<dc:title><![CDATA[Prions: Protein Aggregation and Infectious Diseases]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1152</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1105</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1153?rss=1">
<title><![CDATA[Calcium-Induced Calcium Release in Skeletal Muscle]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1153?rss=1</link>
<description><![CDATA[ 
<P>Calcium-induced calcium release (CICR) was first discovered in skeletal muscle. CICR is defined as Ca<SUP>2+</SUP> release by the action of Ca<SUP>2+</SUP> alone without the simultaneous action of other activating processes. CICR is biphasically dependent on Ca<SUP>2+</SUP> concentration; is inhibited by Mg<SUP>2+</SUP>, procaine, and tetracaine; and is potentiated by ATP, other adenine compounds, and caffeine. With depolarization of the sarcoplasmic reticulum (SR), a potential change of the SR membrane in which the luminal side becomes more negative, CICR is activated for several seconds and is then inactivated. All three types of ryanodine receptors (RyRs) show CICR activity. At least one RyR, RyR1, also shows non-CICR Ca<SUP>2+</SUP> release, such as that triggered by the t-tubule voltage sensor, by clofibric acid, and by SR depolarization. Maximum rates of CICR, at the optimal Ca<SUP>2+</SUP> concentration in the presence of physiological levels of ATP and Mg<SUP>2+</SUP> determined in skinned fibers and fragmented SR, are much lower than the rate of physiological Ca<SUP>2+</SUP> release. The primary event of physiological Ca<SUP>2+</SUP> release, the Ca<SUP>2+</SUP> spark, is the simultaneous opening of multiple channels, the coordinating mechanism of which does not appear to be CICR because of the low probability of CICR opening under physiological conditions. The coordination may require Ca<SUP>2+</SUP>, but in that case, some other stimulus or stimuli must be provided simultaneously, which is not CICR by definition. Thus CICR does not appear to contribute significantly to physiological Ca<SUP>2+</SUP> release. On the other hand, CICR appears to play a key role in caffeine contracture and malignant hyperthermia. The potentiation of voltage-activated Ca<SUP>2+</SUP> release by caffeine, however, does not seem to occur through secondary CICR, although the site where caffeine potentiates voltage-activated Ca<SUP>2+</SUP> release might be the same site where caffeine potentiates CICR.</P>
]]></description>
<dc:creator><![CDATA[Endo, M.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00040.2008</dc:identifier>
<dc:title><![CDATA[Calcium-Induced Calcium Release in Skeletal Muscle]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1176</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1153</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1177?rss=1">
<title><![CDATA[Peptide Hormone Regulation of Angiogenesis]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1177?rss=1</link>
<description><![CDATA[ 
<P>It is now apparent that regulation of blood vessel growth contributes to the classical actions of hormones on development, growth, and reproduction. Endothelial cells are ideally positioned to respond to hormones, which act in concert with locally produced chemical mediators to regulate their growth, motility, function, and survival. Hormones affect angiogenesis either directly through actions on endothelial cells or indirectly by regulating proangiogenic factors like vascular endothelial growth factor. Importantly, the local microenvironment of endothelial cells can determine the outcome of hormone action on angiogenesis. Members of the growth hormone/prolactin/placental lactogen, the renin-angiotensin, and the kallikrein-kinin systems that exert stimulatory effects on angiogenesis can acquire antiangiogenic properties after undergoing proteolytic cleavage. In view of the opposing effects of hormonal fragments and precursor molecules, the regulation of the proteases responsible for specific protein cleavage represents an efficient mechanism for balancing angiogenesis. This review presents an overview of the actions on angiogenesis of the above-mentioned peptide hormonal families and addresses how specific proteolysis alters the final outcome of these actions in the context of health and disease.</P>
]]></description>
<dc:creator><![CDATA[Clapp, C., Thebault, S., Jeziorski, M. C., Martinez De La Escalera, G.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00024.2009</dc:identifier>
<dc:title><![CDATA[Peptide Hormone Regulation of Angiogenesis]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1215</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1177</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1217?rss=1">
<title><![CDATA[Muscle Giants: Molecular Scaffolds in Sarcomerogenesis]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1217?rss=1</link>
<description><![CDATA[ 
<P>Myofibrillogenesis in striated muscles is a highly complex process that depends on the coordinated assembly and integration of a large number of contractile, cytoskeletal, and signaling proteins into regular arrays, the sarcomeres. It is also associated with the stereotypical assembly of the sarcoplasmic reticulum and the transverse tubules around each sarcomere. Three giant, muscle-specific proteins, titin (3&ndash;4 MDa), nebulin (600&ndash;800 kDa), and obscurin (~720&ndash;900 kDa), have been proposed to play important roles in the assembly and stabilization of sarcomeres. There is a large amount of data showing that each of these molecules interacts with several to many different protein ligands, regulating their activity and localizing them to particular sites within or surrounding sarcomeres. Consistent with this, mutations in each of these proteins have been linked to skeletal and cardiac myopathies or to muscular dystrophies. The evidence that any of them plays a role as a "molecular template," "molecular blueprint," or "molecular ruler" is less definitive, however. Here we review the structure and function of titin, nebulin, and obscurin, with the literature supporting a role for them as scaffolding molecules and the contradictory evidence regarding their roles as molecular guides in sarcomerogenesis.</P>
]]></description>
<dc:creator><![CDATA[Kontrogianni-Konstantopoulos, A., Ackermann, M. A., Bowman, A. L., Yap, S. V., Bloch, R. J.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00017.2009</dc:identifier>
<dc:title><![CDATA[Muscle Giants: Molecular Scaffolds in Sarcomerogenesis]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1267</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1217</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1269?rss=1">
<title><![CDATA[The Hepatic Microcirculation: Mechanistic Contributions and Therapeutic Targets in Liver Injury and Repair]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1269?rss=1</link>
<description><![CDATA[ 
<P>The complex functions of the liver in biosynthesis, metabolism, clearance, and host defense are tightly dependent on an adequate microcirculation. To guarantee hepatic homeostasis, this requires not only a sufficient nutritive perfusion and oxygen supply, but also a balanced vasomotor control and an appropriate cell-cell communication. Deteriorations of the hepatic homeostasis, as observed in ischemia/reperfusion, cold preservation and transplantation, septic organ failure, and hepatic resection-induced hyperperfusion, are associated with a high morbidity and mortality. During the last two decades, experimental studies have demonstrated that microcirculatory disorders are determinants for organ failure in these disease states. Disorders include <I>1</I>) a dysregulation of the vasomotor control with a deterioration of the endothelin-nitric oxide balance, an arterial and sinusoidal constriction, and a shutdown of the microcirculation as well as <I>2</I>) an overwhelming inflammatory response with microvascular leukocyte accumulation, platelet adherence, and Kupffer cell activation. Within the sequelae of events, proinflammatory mediators, such as reactive oxygen species and tumor necrosis factor-, are the key players, causing the microvascular dysfunction and perfusion failure. This review covers the morphological and functional characterization of the hepatic microcirculation, the mechanistic contributions in surgical disease states, and the therapeutic targets to attenuate tissue injury and organ dysfunction. It also indicates future directions to translate the knowledge achieved from experimental studies into clinical practice. By this, the use of the recently introduced techniques to monitor the hepatic microcirculation in humans, such as near-infrared spectroscopy or orthogonal polarized spectral imaging, may allow an early initiation of treatment, which should benefit the final outcome of these critically ill patients.</P>
]]></description>
<dc:creator><![CDATA[Vollmar, B., Menger, M. D.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00027.2008</dc:identifier>
<dc:title><![CDATA[The Hepatic Microcirculation: Mechanistic Contributions and Therapeutic Targets in Liver Injury and Repair]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1339</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1269</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1341?rss=1">
<title><![CDATA[Calcium Pumps in Health and Disease]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1341?rss=1</link>
<description><![CDATA[ 
<P>Ca<SUP>2+</SUP>-ATPases (pumps) are key actors in the regulation of Ca<SUP>2+</SUP> in eukaryotic cells and are thus essential to the correct functioning of the cell machinery. They have high affinity for Ca<SUP>2+</SUP> and can efficiently regulate it down to very low concentration levels. Two of the pumps have been known for decades (the SERCA and PMCA pumps); one (the SPCA pump) has only become known recently. Each pump is the product of a multigene family, the number of isoforms being further increased by alternative splicing of the primary transcripts. The three pumps share the basic features of the catalytic mechanism but differ in a number of properties related to tissue distribution, regulation, and role in the cellular homeostasis of Ca<SUP>2+</SUP>. The molecular understanding of the function of the pumps has received great impetus from the solution of the three-dimensional structure of one of them, the SERCA pump. These spectacular advances in the structure and molecular mechanism of the pumps have been accompanied by the emergence and rapid expansion of the topic of pump malfunction, which has paralleled the rapid expansion of knowledge in the topic of Ca<SUP>2+</SUP>-signaling dysfunction. Most of the pump defects described so far are genetic: when they are very severe, they produce gross and global disturbances of Ca<SUP>2+</SUP> homeostasis that are incompatible with cell life. However, pump defects may also be of a type that produce subtler, often tissue-specific disturbances that affect individual components of the Ca<SUP>2+</SUP>-controlling and/or processing machinery. They do not bring cells to immediate death but seriously compromise their normal functioning.</P>
]]></description>
<dc:creator><![CDATA[Brini, M., Carafoli, E.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00032.2008</dc:identifier>
<dc:title><![CDATA[Calcium Pumps in Health and Disease]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1378</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1341</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://physrev.physiology.org/cgi/content/abstract/89/4/1379?rss=1">
<title><![CDATA[Reward Processing by the Opioid System in the Brain]]></title>
<link>http://physrev.physiology.org/cgi/content/abstract/89/4/1379?rss=1</link>
<description><![CDATA[ 
<P>The opioid system consists of three receptors, mu, delta, and kappa, which are activated by endogenous opioid peptides processed from three protein precursors, proopiomelanocortin, proenkephalin, and prodynorphin. Opioid receptors are recruited in response to natural rewarding stimuli and drugs of abuse, and both endogenous opioids and their receptors are modified as addiction develops. Mechanisms whereby aberrant activation and modifications of the opioid system contribute to drug craving and relapse remain to be clarified. This review summarizes our present knowledge on brain sites where the endogenous opioid system controls hedonic responses and is modified in response to drugs of abuse in the rodent brain. We review <I>1</I>) the latest data on the anatomy of the opioid system, <I>2</I>) the consequences of local intracerebral pharmacological manipulation of the opioid system on reinforced behaviors, <I>3</I>) the consequences of gene knockout on reinforced behaviors and drug dependence, and <I>4</I>) the consequences of chronic exposure to drugs of abuse on expression levels of opioid system genes. Future studies will establish key molecular actors of the system and neural sites where opioid peptides and receptors contribute to the onset of addictive disorders. Combined with data from human and nonhuman primate (not reviewed here), research in this extremely active field has implications both for our understanding of the biology of addiction and for therapeutic interventions to treat the disorder.</P>
]]></description>
<dc:creator><![CDATA[Le Merrer, J., Becker, J. A. J., Befort, K., Kieffer, B. L.]]></dc:creator>
<dc:date>2009-09-29</dc:date>
<dc:identifier>info:doi/10.1152/physrev.00005.2009</dc:identifier>
<dc:title><![CDATA[Reward Processing by the Opioid System in the Brain]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>4</prism:number>
<prism:volume>89</prism:volume>
<prism:endingPage>1412</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>1379</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

</rdf:RDF>